Mice Lacking Dystrophin or α Sarcoglycan Spontaneously Develop Embryonal Rhabdomyosarcoma with Cancer-Associated p53 Mutations and Alternatively Spliced or Mutant Mdm2 Transcripts
Authors:
- 1 January 2010
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 176 (1) , 416-434
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AR050202, AR047922)
This publication has 105 references indexed in Scilit:
- PDGFR-A is a therapeutic target in alveolar rhabdomyosarcomaOncogene, 2008
- Genetic Modeling of Ras‐Induced Human Rhabdomyosarcoma2008
- Altered expression of natively glycosylated α dystroglycan in pediatric solid tumorsHuman Pathology, 2007
- PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compoundBritish Journal of Cancer, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Mechanisms of Disease: congenital muscular dystrophies—glycosylation takes center stageNature Clinical Practice Neurology, 2006
- The dystroglycan complex: From biology to cancerJournal of Cellular Physiology, 2005
- Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophiesNature, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrixNature, 1992